Exploring and exploiting plant cyclic peptides for drug discovery and development. Issue 6 (18th February 2021)

• Record Type: Journal Article
• Authors: Zhang, Jingjing; Yuan, Jimin; Li, Zhijie; Fu, Chunjin; Xu, Menglong; Yang, Jing; Jiang, Xin; Zhou, Boping; Ye, Xiufeng; Xu, Chengchao
• Other Names: Xu Chengchao guestEditor.; Jigang Wang guestEditor.
• Is Part Of: Medicinal research reviews. Volume 41:Issue 6(2021)
• Page Start: 3096
• Page End: 3117
• Publication Date: 2021-02-18
• Subjects: cyclotides -- orbitides -- peptide scaffold -- peptide‐based drug -- SFTI‐1; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21792
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Ever since the discovery of insulin, natural peptides have become an important resource for therapeutic development. Decades of research has led to the discovery of a long list of peptide drugs with broad applications in clinics, from antibiotics to hypertension treatment to pain management. Many of these US FDA‐approved peptide drugs are derived from microorganisms and animals. By contrast, the great potential of plant cyclic peptides as therapeutics remains largely unexplored. These macrocyclic peptides typically have rigid structures, good bioavailability and membrane permeability, making them appealing candidates for drug development and engineering. In this review, we introduce the three major classes of plant cyclic peptides and summarize their potential medical applications. We discuss how we can leverage the genome information of many different plants to quickly search for new cyclic peptides and how we can take advantage of the insights gained from their biosynthetic pathways to transform the process of production and drug development. These recent developments have provided a new angle for exploring and exploiting plant cyclic peptides, and we believe that many more peptide drugs derived from plants are about to come.